Sign up for free
for our newsletter!
for our newsletter!
Loading...
Article number:
5600203
CAS No.:
646502-53-6
Formula:
C68H105N11O15
Molecular weight:
1316,63 g/mol
VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADCs with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells. Potential mode of action/Key words: Targeting Tubulin, Cytotoxic
Cfm Oskar Tropitzsch GmbH supplies unique molecules - in this case the cytotoxins for antibodies. These payloads are ultra-toxic drugs, i.e. cytotoxic and/or cytostatic molecules, effective at a low dosage and ...
Cfm Oskar Tropitzsch GmbH also provides linker-drug conjugates. Either as linker-drug conjugate or under contract synthesis arrangements. To take advantage of this service please contact us info@cfmot.de for more information. Some ...